SCHEMBL6029924

SCHEMBL6029924

[CH2]CC1CCN(c2nccs2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.49
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.47
ALDH1A1 P00352 1/20 0.45
DRD2 P14416 1/20 0.45
HTT P42858 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
HRH3 Q9Y5N1 1/20 0.42
GRM5 P41594 1/20 0.42
GRM1 Q13255 1/20 0.42
KMT2A Q03164 1/20 0.41
CHI3L1 P36222 2/20 0.40
CYP3A4 P08684 1/20 0.40
CHIT1 Q13231 1/20 0.40
CHI3L2 Q15782 1/20 0.40
CHIA Q9BZP6 1/20 0.40
POLB P06746 1/20 0.39
APEX1 P27695 1/20 0.39
RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1700773 0.83 HPGD (0.51) MEN1HPGDHSD17B10ALDH1A1DRD2
SCHEMBL28153054 0.81 HSD17B10 (0.54) MEN1HPGDHSD17B10ALDH1A1DRD2
SCHEMBL4423455 0.81 DRD2 (0.49) MEN1HPGDHSD17B10ALDH1A1DRD2
SCHEMBL26123760 0.78 HSD17B10 (0.55) MEN1HPGDHSD17B10ALDH1A1DRD2
SCHEMBL29102030 0.78
SCHEMBL31421086 0.78 HPGD (0.43) MEN1HPGDHSD17B10ALDH1A1DRD2
SCHEMBL3060177 0.77 HPGD (0.51) MEN1HPGDHSD17B10ALDH1A1DRD2
SCHEMBL2036931 0.77 HPGD (0.55) MEN1HPGDHSD17B10ALDH1A1DRD2
SCHEMBL20243707 0.77 HPGD (0.51) MEN1HPGDHSD17B10ALDH1A1DRD2
SCHEMBL28982953 0.77 HPGD (0.52) MEN1HPGDHSD17B10ALDH1A1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7056937-B2 Sulfonylquinoxalone derivatives as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2006-06-06 US claimed
US-20040147519-A1 Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2004-07-29 US claimed
US-7056937-B2 Sulfonylquinoxalone derivatives as bradykinin antagonists ELAN PHARMACEUTICALS, INC. (US) 2006-06-06 US disclosed
US-20040147519-A1 Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists ELAN PHARMACEUTICALS, INC. 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147519-A1 Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists BDKRB2, BDKRB1, HRH2 MEN1 1632/4885HPGD 73/4885HSD17B10 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.